A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Status:
Completed
Trial end date:
2012-05-31
Target enrollment:
Participant gender:
Summary
This study will assess the preliminary anti-tumor activity and safety profile of a
combination of bevacizumab and dacarbazine in participants with unresectable/metastatic
melanoma not previously treated with chemotherapy for metastatic disease.